MedElevator
Войти в исследования Anti-cancer drugs · 2005
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gu Wen-Zhen, Joseph Ingrid, Wang Yi-Chun, Frost David, Sullivan Gerard M, Wang Le, Lin Nan-Horng, Cohen Jerry, Stoll Vincent S, Jakob Clarissa G, Muchmore Steven W, Harlan John E, Holzman Tom, Walten Karl A, Ladror Uri S, Anderson Mark G, Kroeger Paul, Rodriguez Luis E, Jarvis Kenneth P, Ferguson Debra, Marsh Kennan, Ng Shichung, Rosenberg Saul H, Sham Hing L, Zhang Haiying
Аннотация
Ras mutation has been detected in approximately 20-30% of all human carcinomas, primarily in pancreatic, colorectal, lung and bladder carcinomas. The indirect inhibition of Ras activity by inhibiting farnesyltransferase (FTase) function is one therapeutic intervention to control tumor growth. Here we report the preclinical anti-tumor activity of our most advanced FTase inhibitor (FTI), ABT-100, and a direct comparison with the current clinical candidates. ABT-100 is a highly selective, potent and orally bioavailable FTI. It broadly inhibits the growth of solid tumors in preclinical animal models. Thus, ABT-100 is an attractive candidate for further clinical evaluation. In addition, our results provide plausible insights to explain the impressive potency and selectivity of ABT-100. Finally, we have demonstrated that ABT-100 significantly suppresses the expression of vascular endothelial growth factor (VEGF) mRNA and secretion of VEGF protein, as well as inhibiting angiogenesis in the animal model.